Barclays’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,005,836
| Closed | -$166M | – | 5140 |
|
|
2021
Q2 | $166M | Buy |
1,005,836
+360,272
| +56% | +$60.1M | 0.08% | 201 |
|
|
2021
Q1 | $99M | Buy |
645,564
+586,915
| +1,001% | +$79.7M | 0.05% | 262 |
|
|
2020
Q4 | $7.36M | Buy |
58,649
+42,385
| +261% | +$4.74M | ﹤0.01% | 1307 |
|
|
2020
Q3 | $1.65M | Sell |
16,264
-3,491
| -18% | -$356K | ﹤0.01% | 2269 |
|
|
2020
Q2 | $1.92M | Sell |
19,755
-1,125
| -5% | -$105K | ﹤0.01% | 2160 |
|
|
2020
Q1 | $1.73M | Sell |
20,880
-79,120
| -79% | -$7.72M | ﹤0.01% | 2416 |
|
|
2019
Q4 | $11.1M | Buy |
100,000
+42,715
| +75% | +$4.39M | 0.01% | 1315 |
|
|
2019
Q3 | $5.68M | Sell |
57,285
-5,014
| -8% | -$498K | ﹤0.01% | 1743 |
|
|
2019
Q2 | $6.18M | Buy |
62,299
+23,558
| +61% | +$2.25M | ﹤0.01% | 1681 |
|
|
2019
Q1 | $4.27M | Buy |
38,741
+620
| +2% | +$64.8K | ﹤0.01% | 1780 |
|
|
2018
Q4 | $3.5M | Buy |
38,121
+13,162
| +53% | +$1.33M | ﹤0.01% | 1880 |
|
|
2018
Q3 | $2.75M | Sell |
24,959
-45,858
| -65% | -$4.77M | ﹤0.01% | 2505 |
|
|
2018
Q2 | $6.61M | Buy |
70,817
+53,364
| +306% | +$4.6M | 0.01% | 1511 |
|
|
2018
Q1 | $1.45M | Buy |
17,453
+9,489
| +119% | +$843K | ﹤0.01% | 2797 |
|
|
2017
Q4 | $725K | Sell |
7,964
-26,243
| -77% | -$2.18M | ﹤0.01% | 3445 |
|
|
2017
Q3 | $2.6M | Buy |
34,207
+4,944
| +17% | +$374K | ﹤0.01% | 2091 |
|
|
2017
Q2 | $2.19M | Sell |
29,263
-2,156
| -7% | -$149K | ﹤0.01% | 2162 |
|
|
2017
Q1 | $2.05M | Sell |
31,419
-28,858
| -48% | -$1.7M | ﹤0.01% | 2074 |
|
|
2016
Q4 | $3.32M | Buy |
60,277
+34,522
| +134% | +$1.89M | ﹤0.01% | 1695 |
|
|
2016
Q3 | $1.46M | Sell |
25,755
-2,956
| -10% | -$145K | ﹤0.01% | 2272 |
|
|
2016
Q2 | $1.2M | Sell |
28,711
-1,901
| -6% | -$87.6K | ﹤0.01% | 2454 |
|
|
2016
Q1 | $1.29M | Buy |
30,612
+24,114
| +371% | +$1.02M | ﹤0.01% | 2323 |
|
|
2015
Q4 | $293K | Sell |
6,498
-896
| -12% | -$37.6K | ﹤0.01% | 3607 |
|
|
2015
Q3 | $281K | Sell |
7,394
-2,661
| -26% | -$107K | ﹤0.01% | 3849 |
|
|
2015
Q2 | $362K | Buy |
10,055
+9,470
| +1,619% | +$300K | ﹤0.01% | 3732 |
|
|
2015
Q1 | $16K | Sell |
585
-528
| -47% | -$14.7K | ﹤0.01% | 5966 |
|
|
2014
Q4 | $27K | Buy |
+1,113
| New | +$25.1K | ﹤0.01% | 6143 |
|
Other funds holding PRAH
Barclays's PRAH Position: Q3 2021 in Review
Barclays sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 1,005,836 shares — an estimated $166M sold.
Barclays first reported a position in PRAH in Q4 2014 and held it in 27 quarters. The position peaked at $166M in Q2 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- Barclays reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Barclays sold 1,005,836 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $166M.
- Barclays first reported a position in PRA Health Sciences, Inc. in Q4 2014 and held it in 27 quarters.
- Barclays's PRA Health Sciences, Inc. position peaked at $166M in Q2 2021.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on Barclays's 13F filing for Q3 2021, filed 9 Nov 2021.